OVERVIEW
Stocktwits Top 25 Week 33
Welcome to the Stocktwits Top 25 Newsletter for Week 33 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 33:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
S&P 500
ST Top 25 S&P 500 💪
The S&P 500 Top 25 list (+5.53%) outperformed the S&P 500 index (+3.93%).
There were 5 major changes to the list this week.
Check out how the momentum meter has performed vs. the S&P 500 index.
STOCKTWITS EDGE
Elevate Your Trading Game 👀
Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100 🤖
The Nasdaq 100 Top 25 list (+5.26%) underperformed the Nasdaq 100 index (+5.38%).
There were 3 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000 🦐
The Russell 2000 Top 25 list (+9.54%) outperformed the Russell 2000 index (+2.93%).
There were 3 major changes to the list this week.
Top Dawg Of The Week 🐶
The Top 25 lists' Top Dawg was Emergent BioSolutions, which rallied 51.48%. 📈
The small-cap biotech stock caught a bid with its peers after the World Health Organization (WHO) declared a public health emergency in response to an mpox outbreak in Africa.
Emergent Biosolutions owns one of two vaccines that have been recommended by the Centers for Disease Control and Prevention (CDC). 💉
$EBS is up 347.50% YTD.
Get In Touch 📬
Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲
Help us deliver the best content possible by completing this brief survey. 📝
Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧
Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍
Disclaimer: Stocktwits, Inc. (“Stocktwits”) operates the stocktwits.com website and Stocktwits mobile device applications (the “Apps”). Stocktwits is not a securities broker-dealer, investment adviser, or any other type of financial professional. No content on the Stocktwits platform should be considered an offer, solicitation of an offer, or advice to buy or sell securities or any other type of investment or financial product. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋
